Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Completed · Phase 3 · Has a placebo group

Conditions studied: Parkinson's Disease (PD)

In brief

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study measures the efficacy, safety, and tolerability of ABBV-951 versus oral Levodopa (LD)/Carbidopa (CD) \[LD/CD\] in advanced PD participants to achieve reduction in motor fluctuations. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given subcutaneously (under the skin) for the treatment of Parkinson's Disease. Adult participants with advanced PD will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 80 sites across the world. In one arm, participants will receive ABBV-951 solution as a continuous infusion under the skin plus oral placebo capsules for LD/CD. In the second arm, participants will receive placebo solution for ABBV-951 as a continuous infusion under the skin plus oral capsules containing LD/CD tablets. The treatment duration is 12 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.

Key facts

Study ID

NCT04380142

Run by

AbbVie

People needed

174

Starts

2020-10-19

Expected to finish

2021-09-29

Last updated by the study team

2022-11-18

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of idiopathic Parkinson's Disease (PD) that is levodopa-responsive.
• Participant must be taking a minimum of 400 milligrams/day (mg/day) of Levodopa (LD) equivalents and be judged by the investigator to have motor symptoms inadequately controlled by current therapy, have a recognizable/identifiable "Off" and "On" states (motor fluctuations), and have an average "Off" time of at least 2.5 hours/day over 3 consecutive PD Diary days with a minimum of 2 hours each day.
• Participant or caregiver, if applicable, demonstrates the understanding and correct use of the delivery system, including the insertion of the cannula into the participant's abdomen, as assessed by the investigator or designee during the Screening period.

You may not qualify if…

• Clinically significant, unstable medical conditions or any other reason that the investigator determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study drug.
• History of allergic reaction or significant sensitivity to LD or constituents of the study drug (and its excipients) and/or other products in the same class.
• Participant has not received deep brain stimulation, CD/LD enteral suspension, or any other PD medication as continuous daily infusion, whether commercially available or investigational. Previous exposure to ABBV-951 is not allowed.

Where it is running

• University of South Alabama /ID# 216757 — Mobile, Alabama, United States
• Xenoscience, Inc /ID# 217110 — Phoenix, Arizona, United States
• Barrow Neurological Institute /ID# 216566 — Phoenix, Arizona, United States
• HonorHealth /ID# 216642 — Phoenix, Arizona, United States
• Movement Disorders Center of Arizona /ID# 216503 — Scottsdale, Arizona, United States
• Banner Sun Health Res Inst /ID# 216507 — Sun City, Arizona, United States
• University of Arkansas for Medical Sciences /ID# 216501 — Little Rock, Arkansas, United States
• The Parkinson's & Movement Disorder Institute - Fountain Valley /ID# 216705 — Fountain Valley, California, United States
• Neuro Pain Medical Center /ID# 216551 — Fresno, California, United States
• University of California, San /ID# 216598 — La Jolla, California, United States
• Loma Linda University Medical /ID# 216500 — Loma Linda, California, United States
• Collaborative Neuroscience Research - Long Beach /ID# 216970 — Long Beach, California, United States
• University of California, Los Angeles /ID# 216674 — Los Angeles, California, United States
• SC3 Research Group - Pasadena /ID# 216821 — Pasadena, California, United States
• Cedars-Sinai Medical Center-West Hollywood /ID# 216561 — West Hollywood, California, United States
• University of Colorado Hospital /ID# 216527 — Aurora, Colorado, United States
• Alpine Clinical Research Center /ID# 216637 — Boulder, Colorado, United States
• Denver Neurological Research, LLC /ID# 216784 — Denver, Colorado, United States
• Rocky Mountain Movement Disorders Center /ID# 216737 — Englewood, Colorado, United States
• Christiana Care Health Service /ID# 216515 — Newark, Delaware, United States
• Georgetown University Hospital /ID# 216632 — Washington D.C., District of Columbia, United States
• Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 216517 — Boca Raton, Florida, United States
• Brain Matters Research /ID# 217089 — Delray Beach, Florida, United States
• Fixel Institute for Neurological Diseases /ID# 216514 — Gainesville, Florida, United States
• University of Alabama at Birmingham - Main /ID# 216595 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.